LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer
Expanded authorization introduces a treatment option for women experiencing moderate to severe hot flashes and/or night sweats caused by adjuvant endocrine therapy (AET) related to breast cancer LYNKUET® is the first NK-1 and NK-3 receptor antagonist indicated in the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause Expanded indication is supported by […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
